Globeflex Capital L P acquired a new position in shares of Emergent Biosolutions Inc. (NYSE:EBS - Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 241,298 shares of the biopharmaceutical company's stock, valued at approximately $2,022,000. Globeflex Capital L P owned about 0.47% of Emergent Biosolutions at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in EBS. CWM LLC grew its holdings in Emergent Biosolutions by 5.5% during the fourth quarter. CWM LLC now owns 18,009 shares of the biopharmaceutical company's stock worth $223,000 after acquiring an additional 942 shares during the period. Franklin Resources Inc. boosted its position in shares of Emergent Biosolutions by 2.3% in the 4th quarter. Franklin Resources Inc. now owns 78,945 shares of the biopharmaceutical company's stock worth $976,000 after buying an additional 1,764 shares in the last quarter. SG Americas Securities LLC boosted its position in shares of Emergent Biosolutions by 4.6% in the 1st quarter. SG Americas Securities LLC now owns 42,394 shares of the biopharmaceutical company's stock worth $352,000 after buying an additional 1,865 shares in the last quarter. Deutsche Bank AG grew its stake in Emergent Biosolutions by 1.1% in the 4th quarter. Deutsche Bank AG now owns 181,744 shares of the biopharmaceutical company's stock valued at $2,246,000 after acquiring an additional 1,941 shares during the last quarter. Finally, Values First Advisors Inc. increased its holdings in Emergent Biosolutions by 0.9% during the 1st quarter. Values First Advisors Inc. now owns 307,880 shares of the biopharmaceutical company's stock valued at $2,555,000 after acquiring an additional 2,834 shares in the last quarter. 78.40% of the stock is owned by hedge funds and other institutional investors.
Insider Buying and Selling
In other news, SVP Paul Anthony Williams sold 3,000 shares of the stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $8.40, for a total value of $25,200.00. Following the completion of the sale, the senior vice president owned 159,098 shares of the company's stock, valued at $1,336,423.20. This represents a 1.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.00% of the stock is owned by corporate insiders.
Wall Street Analysts Forecast Growth
A number of equities analysts have issued reports on the stock. UBS Group restated a "buy" rating on shares of Emergent Biosolutions in a research report on Tuesday, June 2nd. HC Wainwright cut their price target on Emergent Biosolutions from $12.00 to $10.00 and set a "buy" rating for the company in a report on Monday, August 10th. Weiss Ratings raised Emergent Biosolutions from a "sell (d-)" rating to a "sell (d)" rating in a research note on Friday. JPMorgan Chase & Co. began coverage on shares of Emergent Biosolutions in a research note on Friday. They issued an "underweight" rating for the company. Finally, Benchmark restated a "buy" rating on shares of Emergent Biosolutions in a report on Tuesday, June 2nd. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of "Hold" and an average target price of $10.00.
Get Our Latest Report on EBS
Emergent Biosolutions Trading Up 1.9%
NYSE EBS opened at $5.18 on Tuesday. The company has a market cap of $265.49 million, a P/E ratio of -1.46 and a beta of 2.35. Emergent Biosolutions Inc. has a 12 month low of $4.36 and a 12 month high of $14.06. The company has a debt-to-equity ratio of 1.70, a current ratio of 5.42 and a quick ratio of 2.95. The company has a 50-day moving average of $7.04 and a 200-day moving average of $8.21.
Emergent Biosolutions (NYSE:EBS - Get Free Report) last released its earnings results on Wednesday, August 5th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.68. Emergent Biosolutions had a negative net margin of 22.95% and a positive return on equity of 16.35%. The business had revenue of $234.30 million for the quarter, compared to analysts' expectations of $177.50 million. As a group, equities analysts predict that Emergent Biosolutions Inc. will post -4.63 earnings per share for the current year.
About Emergent Biosolutions
(
Free Report)
Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company's portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.
Key commercial products in Emergent's lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.
Recommended Stories
Want to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent Biosolutions Inc. (NYSE:EBS - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Emergent Biosolutions, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Emergent Biosolutions wasn't on the list.
While Emergent Biosolutions currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
